Island Pharmaceuticals Revenue
Biotechnology Research • 
Melbourne, Victoria, Australia • 1-10 Employees
Island Pharmaceuticals revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | $2,962,900 |
Key Contact at Island Pharmaceuticals
David Foster
Chief Executive Officer and Managing Director
Company overview
| Headquarters | 697 Burke Road Camberwell,, Suite 201,, Melbourne, New South Wales 3124, AU |
| Phone number | +615103936523 |
| Websites | |
| NAICS | 541714 |
| Employees | 1-10 |
| Socials |
Island Pharmaceuticals Email Formats
Island Pharmaceuticals uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@islandpharmaceuticals.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@islandpharmaceuticals.com | 66.7% |
{first initial}{last name} | jdoe@islandpharmaceuticals.com | 33.3% |
About Island Pharmaceuticals
Island (ASX: ILA) is a drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases. We have a lead asset – ISLA-101 - that was initially developed by our wholly-owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquitoes (or vector) borne diseases. Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience. Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Island Pharmaceuticals has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Explore Island Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.
Island Pharmaceuticals Tech Stack
Discover the technologies and tools that power Island Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
CDN
PaaS
Security
JavaScript libraries
Tag managers
JavaScript libraries
CDN
Security
JavaScript libraries
Font scripts
UI frameworks
Saudi Arabia
Frequently asked questions
4.8
40,000 users
